JinYao Pharmaceuticals' stock plummeted sharply after having hit the limit-up for 7 consecutive days previously

China Medicine Industry ( 600488 ) The stock hit the daily limit up at the opening on the 8th, then quickly plunged. As of the latest report, the stock has fallen more than 5%, with a trading volume of over 2 billion yuan. Previously, the stock had hit the daily limit up for seven consecutive trading days.

The company issued a risk warning on the evening of the 7th, stating that from March 26 to April 7, 2026, the company’s stock price hit the daily limit up for seven consecutive trading days, with a total increase of 93.69% during that period. The turnover rate continued to increase, reaching 16.15% in the most recent trading day. The “drum-beating” effect and market irrational speculation are obvious, and trading risks are extremely high. The company’s free float is small, and after speculation, there is a risk of rapid decline in stock price at any time.

The company’s latest operating performance has declined significantly, but the fundamentals have not changed substantially. The stock price increase has already deviated noticeably from the company’s actual operations. In the first three quarters of 2025, the company achieved operating revenue of 2.23B yuan, a year-on-year decrease of 13.24%. The net profit attributable to shareholders of the listed company was 69.54 million yuan, down 62.75% year-on-year. The net profit attributable to shareholders after deducting non-recurring gains and losses was 136 million yuan, down 26.06% year-on-year.

The company has noticed that the market has labeled it as an innovative drug concept and is speculating on it. Currently, the company’s research and development mainly focuses on generic drugs, with no ongoing innovative drug projects, and related speculation involves obvious misinterpretation. The company’s main business is the research, production, and sales of steroid hormones, amino acid raw materials, and formulations. At the same time, the company is aware of market discussions about the prices of hormone raw materials. Currently, the prices of steroid hormone raw materials remain generally stable, which has no impact on the company’s operating performance.